7.99

4.55% -0.36

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $7.99, with a volume of 79,161. It is down -4.55% in the last 24 hours and down -22.09% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$8.35

Open:

$8.7

24h Volume:

79,161

Relative Volume:

1.06

Market Cap:

$70.27M

Revenue:

$140.46M

Net Income/Loss:

$-146.34M

P/E Ratio:

-6.2913

EPS:

-1.27

Net Cash Flow:

$-117.73M

1W Performance:

-11.21%

1M Performance:

-22.09%

6M Performance:

-32.05%

1Y Performance:

-60.05%

1-Day Range:

$7.92

$8.70

1-Week Range:

$7.611

$10.38

52-Week Range:

$7.611

$25.50

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

279

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	7.97	70.27M	140.46M	-146.34M	-117.73M	-1.27
VRTX Vertex Pharmaceuticals Inc	475.53	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.52	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	616.37	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	241.91	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	268.23	29.71B	3.32B	-860.46M	-1.04B	-8.32

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Feb 27, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 26, 2025

Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year - Investing.com

Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025

Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? - StockTitan

Feb 24, 2025

Karyopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 24, 2025

Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025

Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025

Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India

Feb 20, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Feb 20, 2025